Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Chemical Exposure Prevention Clear all
Completed Phase 3 Interventional

Next Generation Ingestible Sensors for Medication Adherence Measurement

NCT05592613
View directory record Official record
Conditions
HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions
Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART)
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 7, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

NCT02367807
View directory record Official record
Conditions
HIV
Interventions
Emtricitabine and tenofovir disoproxil fumarate
Drug
Lead sponsor
Philadelphia Fight
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women

NCT03060785
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate/Emtricitabine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 7, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

NCT05108935
View directory record Official record
Conditions
Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions
Suboxone, Truvada, Mavyret
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

NCT03771638
View directory record Official record
Conditions
Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
Drug · Other
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) Rapid Access

NCT05528562
View directory record Official record
Conditions
Drug Use, Pre-exposure Prophylaxis (PrEP), Opioid Use Disorder
Interventions
PrEP Rapid Access, HIV self-testing, Dried blood spot testing
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Parrying the Pitfalls of PrEP: Project PEACH

NCT05072093
View directory record Official record
Conditions
HIV, STI
Interventions
PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarkers for Event-driven PrEP Adherence

NCT04298697
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 7, 2026, 11:46 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Got Doxy- 'Flipping the Script' on STI PEP

NCT07215325
View directory record Official record
Conditions
Sexually Transmitted Infections (STI)
Interventions
Doxycycline monohydrate 200 mg, Observation
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 7, 2026, 11:46 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

NCT01602822
View directory record Official record
Conditions
HIV
Interventions
Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Drug
Lead sponsor
Kenneth H. Mayer, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 7, 2026, 11:46 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

NCT05783817
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Carolyn Rodriguez
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

NCT00477607
View directory record Official record
Conditions
Ototoxicity, Unspecified Adult Solid Tumor
Interventions
alpha-lipoic acid, Audiology, laboratory biomarker analysis, Placebo
Drug · Behavioral · Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Results available

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Genvoya
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

NCT01327651
View directory record Official record
Conditions
HIV Infections
Interventions
Daily dosing, Time-driven dosing, Event-driven dosing
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

NCT01772823
View directory record Official record
Conditions
HIV Infection
Interventions
3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 22 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 7, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safer Conception Intervention for HIV-1 Serodiscordant Couples

NCT03030768
View directory record Official record
Conditions
HIV Seropositivity, Pregnancy, High-Risk
Interventions
PrEP, Counseling on timed condomless sex, ART and PrEP adherence
Drug · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456
View directory record Official record
Conditions
HIV Infection
Interventions
PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 17 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 7, 2026, 11:46 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Savannah Environmental Nutrition Study (SENS): Nutrition Intervention to Reduce Air Pollution-Related Airway Inflammation and Oxidative Stress

NCT07797413
View directory record Official record
Conditions
Air Pollution Exposure, Oxidative Stress, Airway Inflammation
Interventions
Antioxidant- and Nutrient-Rich Food-Based Nutrition Intervention
Other
Lead sponsor
Georgia Southern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 11:46 PM EDT
Withdrawn Phase 2 Interventional

Celecoxib in Preventing Skin Cancer

NCT00025051
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 7, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals

NCT02621242
View directory record Official record
Conditions
HIV
Interventions
Upper endoscopy, Anoscopy, Truvada
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

NCT00594646
View directory record Official record
Conditions
HIV Infections
Interventions
TRUVADA + Raltegravir
Drug
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

NCT02401230
View directory record Official record
Conditions
HIV
Interventions
Truvada, Gel lubricant
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 7, 2026, 11:46 PM EDT